Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Oncolys BioPharma Inc. Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.	Japan	4588
ONCOLYTICS BIOTECH INC Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.	United States of America	ONCY
Onconetix, Inc. Develops diagnostics and therapeutics for men's health and oncology markets.	United States of America	ONCO
Oncopeptides Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.	Sweden	ONCO
Onesano S.A. Develops patented nutritional products for humans, animals, and agriculture.	Poland	SKT
OnKure Therapeutics, Inc. Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.	United States of America	OKUR
ONO PHARMACEUTICAL CO., LTD. Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.	Japan	4528
OPKO Health Inc. Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.	Israel	OPK
OPKO HEALTH, INC. A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.	United States of America	OPK
Opthea Ltd Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.	United States of America	OPT